Download full-text PDF |
Source |
---|
J Vet Med Sci
December 2024
Laboratory of Veterinary Physiology, Faculty of Applied Biological Sciences, Gifu University.
Int J Mol Sci
November 2024
Unidad de Cartografía Cerebral, Instituto Pluridisciplinar, Universidad Complutense de Madrid, 28040 Madrid, Spain.
4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP induces acute local glucose hypermetabolism and significant brain damage, while i.
View Article and Find Full Text PDFFront Neurosci
November 2024
GliaPharm SA, Geneva, Switzerland.
Introduction: Glucose Transporter 1-Deficiency Syndrome (GLUT1-DS) is a rare genetic disorder caused by mutations in the gene encoding for GLUT1 and characterized by impaired glucose uptake in the brain. This leads to brain hypometabolism and the development of symptoms that include epilepsy, motor dysfunctions and cognitive impairment. The development of patient-specific models is a valuable tool for understanding the pathophysiology of rare genetic disorders and testing new therapeutic interventions.
View Article and Find Full Text PDFBioessays
February 2025
Division of Multicellular Circuit Dynamics, National Institute for Physiological Sciences, Okazaki, Japan.
Sci Rep
November 2024
State Key Laboratory of Space Medicine, Astronaut Research and Training Center, 100094, Beijing, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!